Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ranbaxy Family Feud: Transparency And Ethics “Continuously Negated” Says Younger Brother

Executive Summary

The Singh brothers of Ranbaxy are now engaged in a bitter feud, with the younger sibling Shivinder hauling his brother Malvinder to the National Company Law Tribunal over alleged mismanagement of group firms. It remains to be seen how things play out but Daiichi Sankyo, which is pressing for enforcement of an arbitration award against the brothers, may well claim "we told you so."

You may also be interested in...

Ranbaxy Brothers Arrested, Downward Spiral Intensifies

The Singh brothers of Ranbaxy have been arrested over allegations of financial fraud and things appear headed further downhill. Daiichi Sankyo is also separately pursuing enforcement of damages against the brothers.

India’s Top Court Tells Singhs To Come Up With Plan To Pay Daiichi, Uphold Nation’s ‘Honor’

India’s Supreme Court has told Malvinder Singh and Shivinder Singh, once corporate billionaires, to work out a strategy within two weeks to pay Japanese drug giant Daiichi Sankyo a $500m arbitration award and "uphold the nation’s honor."

Daiichi Demands Court Block Fortis Sale Until Singhs Pay $550m Arbitration Award

Daiichi Sankyo has demanded that an Indian court block a mega-deal to sell Indian hospital chain Fortis to a local healthcare provider until the hospital chain’s founders, Malvinder Singh and Shivinder Singh, pay a $550m international arbitration award to the Japanese drugmaker.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts